High glucose-to-lymphocyte ratio associated with poor prognosis in patients with sepsis-associated AKI
A recently published investigation delves into the potential link between the glucose-to-lymphocyte ratio (GLR) and the prognosis of patients with sepsis-associated acute kidney injury (SA-AKI). The study underscores GLR's potential as an independent risk factor for predicting 28-day mortality in SA-AKI patients. Elevated GLR levels were associated with poorer prognosis, indicating its value as a prognostic marker in this critical medical condition.
This study was published in the journal Zhonghua Wei Zhong Bing Ji Jiu Yi Xue by Zhang L. and colleagues. The study aimed to evaluate whether GLR levels could serve as a predictor of patient outcomes in this critical medical condition. The study examined 1,524 SA-AKI patients, aged 18 years and above, utilizing the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database. Patients were categorized into three groups based on GLR levels: GLR1 (≤ 4.97×10[-9] mmol), GLR2 (4.97×10[-9] mmol < GLR < 9.75×10[-9] mmol), and GLR3 (≥ 9.75×10[-9] mmol). The study assessed mortality rates at 28 days, 90 days, 180 days, and 1 year among the patient groups. Additionally, multivariate logistic regression analysis and receiver operator characteristic curve (ROC curve) analysis were employed to determine GLR's predictive efficacy for 28-day mortality.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.